<DOC>
	<DOC>NCT00361881</DOC>
	<brief_summary>The purpose of this study is to determine whether ME-609 is more efficient than acyclovir and placebo for the treatment of recurrent herpes labialis.</brief_summary>
	<brief_title>Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis</brief_title>
	<detailed_description>This was a randomized, double-blind, active- and vehicle-controlled study comparing the effects of ME-609, acyclovir in ME-609 vehicle, and vehicle alone. Treatment was subject-initiated within 1 hour of experiencing the first signs or symptoms of a herpes recurrence. The subject visited a study clinic as soon as possible after treatment initiation, but no later than midnight of the following day, for evaluation.</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Generally good health History of recurrent herpes labialis with at last three episodes during the prior 12 months Treatment with antivirals or immunosuppressive agents within 2 weeks prior to randomization Pregnant and/or nursing women Continuous daily treatment with pain medication Significant skin condition that occur in the area of herpes recurrences</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>